Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.
You may also be interested in...
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
The latest drug development news and highlights from our US FDA Performance Tracker.
Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC
With significant Phase II results in ulcerative colitis, Arena is planning a Phase III program for its selective S1P receptor modulator etrasimod – a drug that it thinks can best Celgene's S1P-targeting therapy ozanimod on safety and possibly efficacy.